• linkedin
  • Increase Font
  • Sharebar

    Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyes

    Results of a 6-month, phase I/II clinical trial demonstrate that suprachoroidal injection of preservative-free triamcinolone acetonide 4 mg using a proprietary microneedle (CLS-TA, Clearside Biomedical) is well-tolerated, and results in functional and anatomic improvements in eyes with diabetic macular edema (DME). The data also show greater benefit in treatment-naïve eyes, compared with those that were previously treated, reported Charles C. Wykoff, MD, PhD.   

    Dr. Wykoff                                   

    “The suprachoroidal route holds great promise for delivery of pharmaceuticals,” said Dr. Wykoff, director of research, Retina Consultants of Houston; deputy chairman of ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston. “For corticosteroids specifically, it may allow the drug level to be maximized in the retina and minimized in the anterior chamber with the potential to reduce cataract acceleration and the incidence of increased intraocular pressure (IOP).”

    Dr. Wykoff added that the safety review from HULK study showed that multiple suprachoroidal CLS-TA injections were well tolerated and associated with a low incidence of elevated IOP.

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';